NASDAQ:DCOY Decoy Therapeutics Q1 2026 Earnings Report $3.09 -0.02 (-0.64%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$3.09 0.00 (0.00%) As of 09/25/2026 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Decoy Therapeutics EPS ResultsActual EPS-$4.18Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADecoy Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADecoy Therapeutics Announcement DetailsQuarterQ1 2026Date5/8/2026TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Decoy Therapeutics Earnings HeadlinesBest Penny Stocks To Watch Now - September 22ndSeptember 25 at 5:03 AM | americanbankingnews.comDecoy Therapeutics Inducement Warrants Boost Near-Term LiquiditySeptember 23, 2026 | tipranks.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.September 27 at 1:00 AM | Stansberry Research (Ad)Decoy Therapeutics, Inc. Issues Correction to Warrant Inducement Transaction Press ReleaseSeptember 22, 2026 | prnewswire.comDecoy Therapeutics Inc DCOYSeptember 22, 2026 | morningstar.comMDecoy Expands Pan-Filovirus Efforts Through FDA Pathway; Stock UpSeptember 22, 2026 | rttnews.comSee More Decoy Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Decoy Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Decoy Therapeutics and other key companies, straight to your email. Email Address About Decoy TherapeuticsDecoy Therapeutics (NASDAQ:DCOY) is a biotechnology company focused on developing antiviral medicines designed to mimic naturally occurring biological targets used by viruses to infect cells. Its approach is intended to create “decoy” molecules that bind to viruses and help prevent them from interacting with human cells. The company’s research is centered on potential treatments for viral infections, including respiratory diseases. Its product candidates and development programs are based on proprietary decoy-protein technology, although detailed information about specific candidates, clinical-stage programs and commercial products is limited. Decoy Therapeutics is headquartered in the United States and appears to be focused primarily on research and development rather than marketed products. Publicly available information about its operating history, geographic presence and leadership is limited.View Decoy Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/252 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindCostco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem5 Scary-Good Stocks With Strong October Catalysts and Breakout PotentialDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin Settlement Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
